Cabaletta Bio, Inc.

NasdaqGS:CABA Rapporto sulle azioni

Cap. di mercato: US$111.9m

Cabaletta Bio Gestione

Gestione criteri di controllo 2/4

Cabaletta Bio Il CEO è Steven Nichtberger, nominato in Jan2017, e ha un mandato di 7.83 anni. la retribuzione annua totale è $ 4.81M, composta da 12.4% di stipendio e 87.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.76% delle azioni della società, per un valore di $ 3.09M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 4.8 anni.

Informazioni chiave

Steven Nichtberger

Amministratore delegato

US$4.8m

Compenso totale

Percentuale dello stipendio del CEO12.4%
Mandato del CEO7.8yrs
Proprietà del CEO2.8%
Durata media del management3yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

May 22
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Dec 28
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steven Nichtberger rispetto agli utili di Cabaletta Bio?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$1mUS$213k

-US$12m

Compensazione vs Mercato: La retribuzione totale di Steven ($USD 4.81M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: La retribuzione di Steven è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Steven Nichtberger (63 yo)

7.8yrs

Mandato

US$4,808,279

Compensazione

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 3.1m
David Chang
Chief Medical Officer5.4yrsUS$2.10m0%
$ 0
Gwendolyn Binder
President of Science & Technologyno dataUS$2.34m0.041%
$ 45.8k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Anup Marda
Chief Financial Officer5.8yrsUS$1.53mNessun dato
Qing Yuan
Chief Technology Officerless than a yearNessun datoNessun dato
Samik Basu
Chief Scientific Officer3yrsNessun datoNessun dato
Michael Gerard
General Counsel & Secretary3.2yrsNessun datoNessun dato
Heather Harte-Hall
Chief Compliance Officer3yrsNessun datoNessun dato
Nicolette Sherman
Chief Human Resources Officerno dataNessun datoNessun dato
Arun Das
Chief Business Officer2.8yrsNessun datoNessun dato

3.0yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di CABA è considerato esperto (durata media dell'incarico 3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 3.1m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Richard Henriques
Independent Director5.8yrsUS$259.20k0%
$ 0
Carl June
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
Mark Simon
Independent Director6.1yrsUS$260.15k0.29%
$ 327.8k
Brian Daniels
Member of Scientific Advisory Board3.4yrsUS$202.24kNessun dato
Scott Brun
Independent Director3.4yrsUS$255.83k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board4.8yrsNessun datoNessun dato
Jay Siegel
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Drew Weissman
Member of Scientific Advisory Board2.9yrsNessun datoNessun dato
Catherine Bollard
Independent Director5.6yrsUS$255.43k0.0021%
$ 2.3k

4.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CABA sono considerati esperti (durata media dell'incarico 4.8 anni).